Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.

Significant variability in practice exists with respect to filgrastim administration. Definitive studies are therefore required to standardize and improve care, as this has the potential to impact treatment outcomes, patient quality of life, and cost savings.